Carcinoma Renale

(1)

Carcinoma renale

Dr. Aldo Chioni

ASL Toscana Sud Est U.O.C. Oncologia Medica

Grosseto

Supernovae in Oncologia

Pisa 19-20 settembre 2019

(2)

(3)

Nel 2018

(4)

(5)

(6)

(7)

(8)

Novità 2019

(9)

Baseline Characteristics

(10)

Overall Survival

(11)

Overall Survival in Key Subgroups

(12)

Progression-Free Survival

(13)

Progression-Free Survival in Key Subgroups<br />

(14)

Confirmed Objective Response Rate

(15)

Treatment-Related Adverse Events: <br />Incidence ≥20%

(16)

Pembrolizumab plus Axitinib as First-Line Therapy for mRCC: Outcomes in the Combined IMDC Intermediate/Poor Risk and Sarcomatoid Subgroups of KEYNOTE-426

(17)

IMDC Favorable Risk: OS, PFS, and ORR

(18)

(19)

Response: Presence of Sarcomatoid Featuresa

(20)

PFS: Presence of Sarcomatoid Featuresa

(21)

(22)

(23)

(24)

(25)

(26)

(27)

(28)

(29)

(30)

(31)

Biomarker analyses from JAVELIN Renal 101: avelumab + axitinib vs sunitinib <br />in advanced renal cell carcinoma

(32)

(33)

Biomarker assessments and methodology

(34)

PFS according to PD-L1 IHC

(35)

Slide 9

(36)

Slide 12

(37)

Slide 13

(38)

PFS according to expression of select genes

(39)

Slide 17

(40)

Slide 19

(41)

(42)

Possibile algoritmo decisionale

Nature Clin Oncol Rev 2019

(43)

(44)

Linee guida EAU 2019

(45)

(46)

Carcinoma Renale